Navigation Links
Novartis Study Shows QTI571 Significantly Improved Walking Distance in Patients with Life-Threatening Pulmonary Arterial Hypertension
Date:9/25/2011

ributed to the Novartis Group's assets and liabilities as recorded in the Group's consolidated balance sheet, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Novartis

Novartis Pharmaceuticals Corporation researches, develops, manufactures and markets innovative prescription drugs used to treat a number of diseases and conditions, including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease and respiratory. The company's mission is to improve people's lives by pioneering novel healthcare solutions.

Located in East Hanover, New Jersey, Novartis Pharmaceuticals Corporation is an affiliate of Novartis AG, which provides healthcare solutions that address the evolving needs of patients and societies. Focused solely on healthcare, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, consumer health products, preventive vaccines and diagnostic tools. Novartis is the only company with leading positions in these areas. In 2010, the Group's continuing operations achieved net sales of USD 50.6 billion, while approximately USD 9.1 billion (USD 8.1 billion excluding impairment and amortization charges) was invested in R&D throughout the Group. Headquartered in Basel, Switzerland, Novartis Group companies employ approximately 121,000 full-time-equivalent as
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
2. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
3. Emisphere Announces Recruitment of Novartis Phase III Study for Oral Osteoporosis Treatment
4. Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families Lets Fight Flu Together!
5. More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
6. Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
7. Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership
8. US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
9. Results In The New England Journal Of Medicine Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery
10. Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia
11. Novartis Pharmaceuticals Corporation Prevails in Medicaid Pricing Case Before Alabama Supreme Court
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... CITY, Kan. , March 4, 2015   ... a pet therapeutics company focused on the licensing, development ... today announced that it will present at the ... 10-12, 2015, at the Loews Miami Beach Hotel in ... Steven St. Peter , M.D., President and Chief ...
(Date:3/4/2015)... March 4, 2015  Results of the recent study, ... Using MarginProbe for Intra-Operative Positive Margin Detection , were ... the 32 nd Annual Miami Breast Cancer Conference ... Moshe Papa , MD, FACS, Professor of Surgery ... University, reports an analysis of MarginProbe,s efficiency and accuracy ...
(Date:3/4/2015)... 2015 Aethlon Medical, Inc. (OTCQB:AEMD), the pioneer in ... cancer, today announced that James A. Joyce , ... overview at the 27th Annual ROTH Conference on March ... Laguna Niguel, California . To learn more about ... A live webcast of the presentation will be ...
Breaking Medicine Technology:Aratana Therapeutics to Present at the Barclays Global Healthcare Conference 2New Study Shows Breast Re-excision Rates Significantly Reduced in 100 Consecutive Cases 2Aethlon Medical to Present at the 27th Annual ROTH Conference 2
... April 22 Genoptix, Inc. (Nasdaq: GXDX ), a specialized ... for the first quarter 2010 after closing of the NASDAQ Global Select Market ... , , ... , Ph.D., and other members of senior management will take place on the ...
... REDWOOD CITY, Calif. , April 22 Codexis, Inc. announced today ... stock, at $13.00 per share. All shares are being sold by ... an additional 900,000 shares at the initial public offering price to cover overallotments, ... the symbol "CDXS." , , , ...
Cached Medicine Technology:Genoptix, Inc. to Announce First Quarter 2010 Financial Results 2Genoptix, Inc. to Announce First Quarter 2010 Financial Results 3Codexis, Inc. Announces Pricing of Initial Public Offering 2
(Date:3/4/2015)... The report covers spices market upstream ... industry development trend and proposals. The report provides ... definitions, applications and industry chain structure. Global market ... with a focus on history, developments, trends and ... the international and Chinese situation is also offered. ...
(Date:3/4/2015)... CITY, GA (PRWEB) March 04, 2015 ... exclusive advanced microfiber technology and their first compression therapy ... huge success of this collection, SIGVARIS USA is proud ... the MIDTOWN MICROFIBER product line. , Constructed from a ... with all-day comfort in mind. These socks and thigh-highs ...
(Date:3/4/2015)... New Port Richey, FL (PRWEB) March 04, 2015 ... Novus Medical Detox cut the ribbon on their new facility ... West Pasco Chamber of Commerce. The new facility will allow ... mission of helping end the prescription drug abuse epidemic through ... the current reality of drug addiction in the United States, ...
(Date:3/4/2015)... Today Visiopharm announces that Patrik Dahlén, previously the ... Visiopharm Board of Directors as Chairman. Mr. ... positioned to become the fastest growing software company, specializing ... , "Over the last several years, Visiopharm ... ONCOtopix™ Dx, a complete quantitative digital pathology solution for ...
(Date:3/4/2015)... A new dieting routine, called the feast and ... life. Studies conducted by the University of ... help extend life by increasing anti-oxidant production. While increased ... many suffering from obesity are already experiencing life shortening ... an alternative to the new Feast and Famine diet, ...
Breaking Medicine News(10 mins):Health News:World Spices Market Overview & Development 2015-2020 Now Available at DeepResearchReports.com 2Health News:World Spices Market Overview & Development 2015-2020 Now Available at DeepResearchReports.com 3Health News:Building on the Success of MIDTOWN MICROFIBER, SIGVARIS Expands Popular Compression Collection with Longer Foot Length Offerings 2Health News:Novus Medical Detox Hosts Ribbon Cutting Ceremony at Pasco County Facility 2Health News:Novus Medical Detox Hosts Ribbon Cutting Ceremony at Pasco County Facility 3Health News:Visiopharm Appoints Patrik Dahlen as Chairman of the Board 2Health News:Visiopharm Appoints Patrik Dahlen as Chairman of the Board 3Health News:Diet Doc Introduces New Alternative to the Feast and Famine Diet 2Health News:Diet Doc Introduces New Alternative to the Feast and Famine Diet 3
... A white paper that examines various state initiatives to expand ... President and Congress in support of state efforts, was distributed ... , The paper, State Experimentation with Reforms to Expand Access ... a part of any state-based reform. It is a summary ...
... only wear an eye patch for three to four hours ... in a study published on bmj.com today. , ... which is often recommended, is almost certainly excessive, they argue. ... between the eyes and the brain, which is often associated ...
... KENSINGTON, Md., Sept. 14 San Francisco will,get an ... tonight as,Psoriasis Cure Now, a nonprofit patient advocacy group, ... to celebrate. Starting at 9:30 pm, two bands,will perform ... this combination,awareness event, fundraiser and party. The suggested donation ...
... Sept. 14 Arrow International,Inc. (Nasdaq: ARRO ) ... voting advisory firm, has advised its clients to vote ... and for the re-election of Arrow,s current Board of ... 20, 2007. Proxy Governance is the fourth proxy ...
... Across the United States, He,s Riding AROUND IT, ... WASHINGTON, Sept. 14 Australian Geoff Thomas,will stop in ... by cycling to all four corners of the country ... kind to raise awareness for lupus, a chronic autoimmune,disease ...
... Sept. 14 As the political turmoil,surrounding stem cells ... - and treatment - that saved his life. John ... AuthorHouse -, http://www.authorhouse.com ), recounts the courageous five-year battle ... of cancer. Settling into a comfortable retirement with ...
Cached Medicine News:Health News:Internal medicine physicians recommend key elements to guide state initiatives 2Health News:Internal medicine physicians recommend key elements to guide state initiatives 3Health News:No need for children with lazy eye to wear patches all day 2Health News:San Francisco Psoriasis Event Tonight Will Celebrate First National Short Sleeve Day 2Health News:Proxy Governance Joins ISS, Glass Lewis and Egan Jones in Recommending Arrow International Shareholders Vote to Approve the $45.50 Per Share Merger With Teleflex 2Health News:Proxy Governance Joins ISS, Glass Lewis and Egan Jones in Recommending Arrow International Shareholders Vote to Approve the $45.50 Per Share Merger With Teleflex 3Health News:Bicyclist to Stop in DC during 9,000 Mile Lap Around the U.S. 2Health News:The Fight for His Life: Author, Family Battle Disease and Challenge Politics in the Face of Survival 2
... Stryker's cystoscope line combines ... intuitive and durable hardware. ... incorporate a robust, ergonomic ... connection found on Stryker ...
... The new EndoEYE Flexible Video Cystoscope from ... surgical technology. By marrying proprietary video chip ... Olympus is now providing a flexible video ... that of a rigid rod lens system. ...
The Olympus continuous flow cystoscope was especially designed for laser treatment of the prostate and for collagen injection....
... is an advanced transurethral microwave thermotherapy ... benign prostate hyperplasia (BPH). TherMatrx is ... thermotherapy treatment in the United States. ... does not require cutting, heavy sedation ...
Medicine Products: